Obstet Gynecol Sci.  2022 Jul;65(4):355-367. 10.5468/ogs.22071.

Safety and feasibility of laterally extended endopelvic resection for sarcoma in the female genital tract: a prospective cohort study

• Park SJ
• Kim J
• Kim JW
• Kim HS
• Yim GW

• KMID: 2531844
• DOI: http://doi.org/10.5468/ogs.22071

Abstract

Objective
This study aims to evaluate the safety and feasibility of laterally extended endopelvic resection (LEER) for sarcoma in the female genital tract.
Methods
We prospectively recruited gynecologic cancer patients with sarcoma arising from female genital tract who underwent LEER at Seoul National University Hospital from December 2016 to March 2021. Clinicopathologic characteristics, surgical outcomes including postoperative complications and pain control, and survival outcomes of the patients were investigated.
Results
A total of nine patients were registered for this study. The median age was 56 years. Carcinosarcoma (n=2, 22%), leiomyosarcoma (n=2, 22%), and undifferentiated uterine sarcoma (n=2, 22%) were common histology types. Complete resection was achieved in 88.9%. The most common location of pelvic sidewall tumors was infra-iliac acetabulum (66.7%). The pathologic outcome showed a median tumor size of 9.0 cm and internal iliac vessel resection with pelvic sidewall muscle was performed in all patients. The median estimated blood loss was 1,600 mL (range, 300-22,300), and the patients were postoperatively admitted to the intensive care unit for median 1 day (range, 0-8). Complete response was observed in 44.4% (4/9) in radiologic studies after LEER, and median progression-free survival, treatment-related survival, and overall survival were 3.3, 19.6, and 98.9 months, respectively.
Conclusion
LEER was feasible and safe in treating recurrent sarcoma presenting pelvic sidewall invasion with acceptable survival outcomes and manageable postoperative complications.

Keyword

Gynecologic surgical procedure; Pelvic exenteration; Sarcoma; Surgery

Figure

• 

  Fig. 1 Patient flowchart. LEER, laterally extended endopelvic resection.

Reference

References

1. Cramer DW, Cutler SJ. Incidence and histopathology of malignancies of the female genital organs in the United States. Am J Obstet Gynecol. 1974; 118:443–60.

2. Boll D, Verhoeven RH, van der Aa MA, Pauwels P, Karim-Kos HE, Coebergh JW, et al. Incidence and survival trends of uncommon corpus uteri malignancies in the Netherlands, 1989–2008. Int J Gynecol Cancer. 2012; 22:599–606.

3. Mbatani N, Olawaiye AB, Prat J. Uterine sarcomas. Int J Gynaecol Obstet. 2018; 143 (Suppl 2):51–8.

4. Bacalbasa N, Balescu I, Dima S, Popescu I. Ovarian sarcoma carries a poorer prognosis than ovarian epithelial cancer throughout all FIGO stages: a single-center case-control matched study. Anticancer Res. 2014; 34:7303–8.

5. Ha HI, Chang HK, Park SJ, Lim J, Won YJ, Lim MC. The incidence and survival of cervical, ovarian, and endometrial cancer in Korea, 1999–2017: Korea central cancer registry. Obstet Gynecol Sci. 2021; 64:444–53.

6. Francis M, Dennis NL, Hirschowitz L, Grimer R, Poole J, Lawrence G, et al. Incidence and survival of gynecologic sarcomas in England. Int J Gynecol Cancer. 2015; 25:850–7.

7. Board WHO Classification of Tumours Editorial Board. Female genital tumours. Lyon: International Agency for Research on Cancer;2020.

8. Kurman RJ, Carcangiu ML, Herrington CS, Young RH. WHO classification of tumours of female reproductive organs. Lyon: International Agency for Research on Cancer;2014.

9. Hosh M, Antar S, Nazzal A, Warda M, Gibreel A, Refky B. Uterine sarcoma: analysis of 13,089 cases based on surveillance, epidemiology, and end results database. Int J Gynecol Cancer. 2016; 26:1098–104.

10. Sagae S, Yamashita K, Ishioka S, Nishioka Y, Terasawa K, Mori M, et al. Preoperative diagnosis and treatment results in 106 patients with uterine sarcoma in Hokkaido, Japan. Oncology. 2004; 67:33–9.

11. Cho HY, Kim K, Kim YB, No JH. Differential diagnosis between uterine sarcoma and leiomyoma using preoperative clinical characteristics. J Obstet Gynaecol Res. 2016; 42:313–8.

12. Yim GW, Nam EJ, Kim SW, Kim YT. FIGO staging for uterine sarcomas: can the revised 2008 staging system predict survival outcome better? Yonsei Med J. 2014; 55:563–9.

13. Potikul C, Tangjitgamol S, Khunnarong J, Srijaipracharoen S, Thavaramara T, Pataradool K. Uterine sarcoma: clinical presentation, treatment and survival outcomes in thailand. Asian Pac J Cancer Prev. 2016; 17:1759–67.

14. Rizzo A, Nannini M, Astolfi A, Indio V, De Iaco P, Perrone AM, et al. Impact of chemotherapy in the adjuvant setting of early stage uterine leiomyosarcoma: a systematic review and updated meta-analysis. Cancers (Basel). 2020; 12:1899.

15. Vaz J, Tian C, Richardson MT, Chan JK, Mysona D, Rao UN, et al. Impact of adjuvant treatment and prognostic factors in stage i uterine leiomyosarcoma patients treated in commission on cancer^®-accredited facilities. Gynecol Oncol. 2020; 157:121–30.

16. Cybulska P, Sioulas V, Orfanelli T, Zivanovic O, Mueller JJ, Broach VA, et al. Secondary surgical resection for patients with recurrent uterine leiomyosarcoma. Gynecol Oncol. 2019; 154:333–7.

17. Höckel M. Laterally extended endopelvic resection: surgical treatment of infrailiac pelvic wall recurrences of gynecologic malignancies. Am J Obstet Gynecol. 1999; 180:306–12.

18. Höckel M. Long-term experience with (laterally) extended endopelvic resection (LEER) in relapsed pelvic malignancies. Curr Oncol Rep. 2015; 17:435.

19. Cowie P, Eastwood B, Smyth S, Soleymani Majd H. Atypical presentation of intravascular leiomyomatosis mimicking advanced uterine sarcoma: modified laterally extended endopelvic resection with preservation of pelvic neural structures. BMJ Case Rep. 2021; 14 :e244774.

20. Cates JMM. The AJCC 8th edition staging system for soft tissue sarcoma of the extremities or trunk: a cohort study of the SEER database. J Natl Compr Canc Netw. 2018; 16:144–52.

21. Brierley J, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. 8th ed. West Sussex: John Wiley & Sons, Inc;2017.

22. Höckel M. Laterally extended endopelvic resection (LEER)--principles and practice. Gynecol Oncol. 2008; 111:S13–7.

23. Park SJ, Kim HS. Laterally extended endopelvic resection with nephrectomy for vaginal cancer. Gynecol Oncol. 2019; 152:218–9.

24. Park SJ, Mun J, Lee S, Luo Y, Chung HH, Kim JW, et al. Laterally extended endopelvic resection versus chemo or targeted therapy alone for pelvic sidewall recurrence of cervical cancer. Front Oncol. 2021; 11:683441.

25. Strong VE, Selby LV, Sovel M, Disa JJ, Hoskins W, Dematteo R, et al. Development and assessment of memorial sloan kettering cancer center’s surgical secondary events grading system. Ann Surg Oncol. 2015; 22:1061–7.

26. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45:228–47.

27. Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain--united states, 2016. JAMA. 2016; 315:1624–45.

28. Gronchi A, Lo Vullo S, Fiore M, Mussi C, Stacchiotti S, Collini P, et al. Aggressive surgical policies in a retrospectively reviewed single-institution case series of retroperitoneal soft tissue sarcoma patients. J Clin Oncol. 2009; 27:24–30.

29. Radaelli S, Fiore M, Colombo C, Ford S, Palassini E, Sanfilippo R, et al. Vascular resection en-bloc with tumor removal and graft reconstruction is safe and effective in soft tissue sarcoma (STS) of the extremities and retro-peritoneum. Surg Oncol. 2016; 25:125–31.

30. Gronchi A, Miah AB, Dei Tos AP, Abecassis N, Bajpai J, Bauer S, et al. Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS clinical practice guidelines for diagnosis, treatment and follow-up^☆ . Ann Oncol. 2021; 32:1348–65.

31. Asencio Pascual JM, Fernandez Hernandez JA, Blanco Fernandez G, Muñoz Casares C, Álvarez Álvarez R, Fox Anzorena B, et al. Update in pelvic and retroperitoneal sarcoma management: the role of compartment surgery. Cir Esp (Engl Ed). 2019; 97:480–8.

32. Anderson MW, Temple HT, Dussault RG, Kaplan PA. Compartmental anatomy: relevance to staging and biopsy of musculoskeletal tumors. AJR Am J Roentgenol. 1999; 173:1663–71.

33. Enneking WF, Spanier SS, Malawer MM. The effect of the anatomic setting on the results of surgical procedures for soft parts sarcoma of the thigh. Cancer. 1981; 47:1005–22.

34. Höckel M, Wolf B, Schmidt K, Mende M, Aktas B, Kimmig R, et al. Surgical resection based on ontogenetic cancer field theory for cervical cancer: mature results from a single-centre, prospective, observational, cohort study. Lancet Oncol. 2019; 20:1316–26.

35. Leitao MM, Brennan MF, Hensley M, Sonoda Y, Hummer A, Bhaskaran D, et al. Surgical resection of pulmonary and extrapulmonary recurrences of uterine leiomyosarcoma. Gynecol Oncol. 2002; 87:287–94.

36. Ríos I, Rovirosa A, Morales J, Gonzalez-Farre B, Arenas M, Ordi J, et al. Undifferentiated uterine sarcoma: a rare, not well known and aggressive disease: report of 13 cases. Arch Gynecol Obstet. 2014; 290:993–7.

37. Matsuzaki S, Klar M, Matsuzaki S, Roman LD, Sood AK, Matsuo K. Uterine carcinosarcoma: contemporary clinical summary, molecular updates, and future research opportunity. Gynecol Oncol. 2021; 160:586–601.

38. Kanao H, Aoki Y, Fusegi A, Takeshima N. Should indications for laterally extended endopelvic resection (LEER) exclude patients with sciatica? J Gynecol Oncol. 2020; 31:e63.

39. Kanao H, Aoki Y, Omi M, Nomura H, Tanigawa T, Okamoto S, et al. Laparoscopic pelvic exenteration and laterally extended endopelvic resection for postradiation recurrent cervical carcinoma: technical feasibility and short-term oncologic outcome. Gynecol Oncol. 2021; 161:34–8.

40. Vizzielli G, Naik R, Dostalek L, Bizzarri N, Kucukmetin A, Tinelli G, et al. Laterally extended pelvic resection for gynaecological malignancies: a multicentric experience with out-of-the-box surgery. Ann Surg Oncol. 2019; 26:523–30.